INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 449m ago
HOUSE PTR49m ago
SEC 13F49m ago
ROBINHOOD CHAIN49m ago
Public company

ANAPTYSBIO, INC

ANABCIK 0001370053

EDGAR filingsOpen in network
Price$46.45
1 year+93.5%
Disclosed transactions40
Buys / sells0 / 13
Max Insider Score33
Connections with evidence6

ANAB · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
MM
Murphy Christopher M.Chief Financial Officer
ANABANAPTYSBIO, INC
Grant or award
A—
25.8K sh
May 11, 2026May 13, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Murphy Christopher M.Chief Financial Officer · May 13, 2026
  • ← Insider ofevidence
    Gray SusannahDirector · Apr 29, 2026
  • ← Insider ofevidence
    Faga DanielDirector, President, CEO · Jan 9, 2026
  • ← Insider ofevidence
traded May 11, 2026
+2d
SEC FORM 4

Evidence

9
GS
Gray SusannahDirector
ANABANAPTYSBIO, INC
Grant or award
A—
11.3K sh
Apr 27, 2026Apr 29, 2026
traded Apr 27, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
2,321 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
2,321 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
9,200 sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
194.9K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
379.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
379.6K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
305.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
305.5K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
133.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

2
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
133.4K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

14
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Disposition to issuer
D—
11.0K sh
Apr 20, 2026Apr 22, 2026
traded Apr 20, 2026
+2dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$203K
3,155 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

17
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$29K
510 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$149K
2,570 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$164K
2,592 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$215K
3,662 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$63K
1,012 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

9
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Grant or award
A—
34.3K sh
Mar 25, 2026Mar 27, 2026
traded Mar 25, 2026
+2dSEC FORM 4

Evidence

20
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$198K
3,038 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

17
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$6,599
100 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

17
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$29K
490 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

17
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$33K
550 sh
Mar 27, 2026Mar 27, 2026
traded Mar 27, 2026
+0dSEC FORM 4

Evidence

17
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Option exercise
M—
8,525 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

29
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Open-market sale
SELL$163K
3,650 sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

13
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Option exercise
M—
26.8K sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

32
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Open-market sale
SELL$639K
14.3K sh
Jan 8, 2026Jan 9, 2026
traded Jan 8, 2026
+1dSEC FORM 4

Evidence

21
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Option exercise
M—
8,525 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

21
FD
Faga DanielDirector, President, CEO
ANABANAPTYSBIO, INC
Option exercise
M—
26.8K sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
ANABANAPTYSBIO, INC
Grant or award
A—
5,500 sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
WA
Ware J. AnthonyDirector
ANABANAPTYSBIO, INC
Grant or award
A—
4,000 sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Option exercise
M—
6,145 sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

13
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Option exercise
M—
6,145 sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

33
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Open-market sale
SELL$101K
2,235 sh
Jan 7, 2026Jan 8, 2026
traded Jan 7, 2026
+1dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Grant or award
A—
21.4K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

9
LF
Lizzul Paul F.Chief Medical Officer
ANABANAPTYSBIO, INC
Grant or award
A—
29.0K sh
Jan 6, 2026Jan 8, 2026
traded Jan 6, 2026
+2dSEC FORM 4

Evidence

Ware J. Anthony
Director · Jan 8, 2026
  • ← Insider ofevidence
    Lizzul Paul F.Chief Medical Officer · Jan 8, 2026